Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

307 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort.
Aronsohn A, Ancuta I, Caruntu F, Coppola C, Delic D, Digiacomo A, Dusheiko GM, Lengyel G, Marcellin P, Orlandini A, Pruthi J, Silva GF, Tallarico L, Schmitz M, Tatsch F, Korner E, Cheinquer H. Aronsohn A, et al. Among authors: silva gf. J Viral Hepat. 2014 May;21(5):377-80. doi: 10.1111/jvh.12179. Epub 2013 Oct 17. J Viral Hepat. 2014. PMID: 24131506 Clinical Trial.
Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
Pessôa MG, Cheinquer H, Almeida PR, Silva GF, Lima MP, Paraná R, Lacerda MA, Parise ER, Pernambuco JR, Pedrosa SS, Teixeira R, Sette H Jr, Tatsch F. Pessôa MG, et al. Among authors: silva gf. Ann Hepatol. 2012 Jan-Feb;11(1):52-61. Ann Hepatol. 2012. PMID: 22166561 Free article. Clinical Trial.
Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein.
Harrison SA, Abdurakhmanov D, Shiffman ML, Bakulin I, Mazur W, Rodriguez-Torres M, Silva GF, Cheinquer H, Messinger D, Connell EV, McKenna M, Tatsch F, Reddy KR; PROGRESS Investigators. Harrison SA, et al. Among authors: silva gf. J Clin Gastroenterol. 2013 Mar;47(3):271-9. doi: 10.1097/MCG.0b013e31826102eb. J Clin Gastroenterol. 2013. PMID: 22951527
Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1-6 in Brazil.
Peribañez-Gonzalez M, Cheinquer H, Rodrigues L, Lima MP, Álvares-da-Silva MR, Madruga J, Parise ER, Pessoa MG, Furtado J, Villanova M, Ferreira A, Mazzoleni F, Nascimento E, Silva GF, Fredrick L, Krishnan P, Burroughs M, Reuter T. Peribañez-Gonzalez M, et al. Among authors: silva gf. Ann Hepatol. 2021 Jan-Feb;20:100257. doi: 10.1016/j.aohep.2020.09.002. Epub 2020 Sep 17. Ann Hepatol. 2021. PMID: 32949786 Free article. Clinical Trial.
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
Pessoa MG, Ramalho-Madruga JV, Alves K, Nunes EP, Cheinquer H, Brandão-Mello CE, Mendes-Correa MC, Ferraz ML, Ferreira PRA, Álvares-da-Silva MR, Coelho HS, Affonso-de-Araújo ES, Furtado J, Parana R, Silva G, Lari SA, Liu L, Tripathi R, Pilot-Matias T, Cohen DE, Shulman NS, Martinelli A. Pessoa MG, et al. Ann Hepatol. 2018 Oct 16;17(6):959-968. doi: 10.5604/01.3001.0012.7196. Ann Hepatol. 2018. PMID: 30600291 Free article. Clinical Trial.
Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.
Reddy KR, Shiffman ML, Rodriguez-Torres M, Cheinquer H, Abdurakhmanov D, Bakulin I, Morozov V, Silva GF, Geyvandova N, Stanciu C, Rabbia M, McKenna M, Thommes JA, Harrison SA; PROGRESS Study Investigators. Reddy KR, et al. Among authors: silva gf. Gastroenterology. 2010 Dec;139(6):1972-83. doi: 10.1053/j.gastro.2010.08.051. Epub 2010 Sep 30. Gastroenterology. 2010. PMID: 20816836 Clinical Trial.
National Brazilian survey on the outcomes of hepatitis c retreatment in patients non-responders to direct antiviral agents.
Ferraz MLG, Piccoli LZ, Rezende R, Borba LA, Junior AP, Cheinquer H, Silva GF, Ferreira PRA, Villela-Nogueira CA, Mazo DF, Souza FF, Codes L, Ivantes CAP, Gomide GPM, Pereira GHS, Pessôa MG, França AVC, Pinto ADS, Teixeira R, Bittencourt PL. Ferraz MLG, et al. Among authors: silva gf. Braz J Infect Dis. 2022 Jul-Aug;26(4):102388. doi: 10.1016/j.bjid.2022.102388. Epub 2022 Jul 26. Braz J Infect Dis. 2022. PMID: 35905930 Free PMC article.
307 results